Amgen maintained at neutral by Merrill

Amgen Inc. was maintained at neutral by Merrill Lynch analyst Eric Ende after the company's conference call and presentation of more detailed data from the phase 3 trial of p-mab in third-line colorectal cancer. The data slides did more justice to the magnitude of the p-mab benefit, especially on progression free survival data. Merrill believes the data are strong enough to support approval and expect better safety and more convenient dosing. Shares of the Thousand Oaks, Calif., biotechnology company were up 14 cents, or 0.19%, at $72.02 on volume of 9,571,784 shares versus the three-month running average of 10,670,000 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.